Brightgene Bio-medical Technology Co., Ltd.
Clinical trials sponsored by Brightgene Bio-medical Technology Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Meal timing matters: new study tests drug absorption after High-Fat breakfast Results expected Sep 2026 (estimated)
- New pill aims to shed pounds without diabetes Results expected Feb 2027 (estimated)
-
New weekly shot could help shed pounds without diabetes
Disease control CompletedThis early-stage trial tested a new drug called BGM0504, given as a weekly injection, in 30 non-diabetic adults who were overweight or obese. The main goals were to check safety, how the body processes the drug, and any changes in weight. Participants received either a low dose, …
Phase 1 • Sponsor: BrightGene Bio-Medical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Kidney function affects how drug for diabetes and weight loss works
Knowledge-focused CompletedThis study looked at how quickly the drug BGM0504 enters the blood and how long it stays in the body. Researchers compared 34 people with normal kidney function to those with mild or moderate kidney problems. The goal is to understand if kidney function changes how the drug shoul…
Phase 1 • Sponsor: BrightGene Bio-Medical Technology Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
New obesity drug BGM0504 tested for interactions with metformin and warfarin
Knowledge-focused CompletedThis completed Phase 1 trial tested how a new injectable drug, BGM0504, affects stomach emptying and the absorption of two common medications—metformin and warfarin—in 28 overweight or obese adults. Participants received BGM0504 alongside these drugs to measure changes in drug le…
Phase 1 • Sponsor: BrightGene Bio-Medical Technology Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:49 UTC